Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
Neovii was founded following the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals.
Neovii aspires to be a fully integrated global pharmaceutical company with several franchises focused on diseases with unmet needs. We continually support customers up and down the value chain and are always in pursuit of maximizing total patient care.
We believe that our competencies and strengths combined with our values and culture make Neovii an employer of choice.